Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Century Therapeutics To Present Preclinical Data From Its iPSC-Derived Cell Therapy Platform At The 2024 American Association For Cancer Research Annual Meeting

Author: Benzinga Newsdesk | March 06, 2024 02:27am

The upcoming abstracts highlight the Company's end-to-end capabilities in iPSC reprogramming and differentiation, gene editing, protein engineering and computational biology. Additionally, the Company will share new preclinical data on additional Allo-Evasion™ edits that could further support Century's multi-dosing strategy.

Posted In: IPSC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist